Drug Trial Radar · NCT03414645
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
May 1, 2018
Primary completion
Dec 12, 2019
Study completion Feb 20, 2020
Sponsor
- Lead sponsor
- Cambium Bio LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Massachusetts Eye and Ear Infirmary; Oregon Health and Science University; University of Michigan; Duke University; Stanford University; University of Minnesota
- First posted
- Jan 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).
Conditions
- Dry Eye
- Graft-versus-host-disease
- Ocular Discomfort
Interventions
CAM-101 10%Biological
fibrinogen-depleted human platelet lysate
Vehicle ControlBiological
PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
CAM-101 30%Biological
fibrinogen-depleted human platelet lysate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Ocular Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: 42 Days
- Number of Participants With Systemic Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: 42 Days
- Number of Participants With Treatment-related Adverse Events as Assessed Change From Normal to Abnormal With Clinical Significance in Any Ocular ExaminationTime frame: 42 Days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Byers Eye Institute of Stanford University
Palo Alto, California
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts
University of Michigan - Kellogg Clinical Research Center
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Duke University Eye Center
Durham, North Carolina
Oregon Health Sciences University - Casey Eye Institute
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.